Customize your JAMA Network experience by selecting one or more topics from the list below.
Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial. JAMA. 2000;283(13):1695–1702. doi:https://doi.org/10.1001/jama.283.13.1695
Author Affiliations: Department of Medicine, Endocrinology Section, Tulane University, New Orleans, La (Dr Fonseca); Dallas Diabetes Center, Dallas, Tex (Dr Rosenstock); Departments of Biometrics (Dr Patwardhan) and Clinical Research and Development (Dr Salzman), SmithKline Beecham Pharmaceuticals, Collegeville, Pa.
Context Most antidiabetic agents target only 1 of several underlying causes
of diabetes. The complementary actions of the antidiabetic agents metformin
hydrochloride and rosiglitazone maleate may maintain optimal glycemic control
in patients with type 2 diabetes; therefore, their combined use may be indicated
for patients whose diabetes is poorly controlled by metformin alone.
Objective To evaluate the efficacy of metformin-rosiglitazone therapy in patients
whose type 2 diabetes is inadequately controlled with metformin alone.
Design Randomized, double-blind, placebo-controlled trial from April 1997 and
Setting Thirty-six outpatient centers in the United States.
Patients Three hundred forty-eight patients aged 40 to 80 years with a mean fasting
plasma glucose level of 12.0 mmol/L (216 mg/dL), a mean glycosylated hemoglobin
level of 8.8%, and a mean body mass index of 30.1 kg/m2 were randomized.
Interventions Patients were assigned to receive 2.5 g/d of metformin plus placebo
(n = 116); 2.5 g/d of metformin plus 4 mg/d of rosiglitazone (n = 119); or
2.5 g/d of metformin and 8 mg/d of rosiglitazone (n = 113) for 26 weeks.
Main Outcome Measures Glycosylated hemoglobin levels, fasting plasma glucose levels, insulin
sensitivity, and β-cell function, compared between baseline and week
26, by treatment group.
Results Glycosylated hemoglobin levels, fasting plasma glucose levels, insulin
sensitivity, and β-cell function improved significantly with metformin-rosiglitazone
therapy in a dose-dependent manner. The mean levels of glycosylated hemoglobin
decreased by 1.0% in the 4 mg/d metformin-rosiglitazone group and by 1.2%
in the 8 mg/d metformin-rosiglitazone group and fasting plasma glucose levels
by 2.2 mmol/L (39.8 mg/dL) and 2.9 mmol/L (52.9 mg/dL) compared with the metformin-placebo
group (P<.001 for all). Of patients receiving
8 mg/d of metformin-rosiglitazone, 28.1% achieved a glycosylated hemoglobin
level of 7% or less. Dose-dependent increases in body weight and total and
low-density lipoprotein cholesterol levels were observed (P<.001 for both rosiglitazone groups vs placebo). The proportion
of patients reporting adverse experiences was comparable across all groups.
Conclusions Our data suggest that combination treatment with once-daily metformin-rosiglitazone
improves glycemic control, insulin sensitivity, and β-cell function more
effectively than treatment with metformin alone.
Create a personal account or sign in to: